4/A: Neuphoria Therapeutics CEO Corrects Stock Option Reporting Error
SEC Filing (Form 4/A)
Neuphoria Therapeutics' CEO, Spyros Papapetropoulos, files an amended Form 4/A to correct a clerical error in the reporting of stock option acquisitions.
Summary
- Spyros Papapetropoulos, the President and CEO of Neuphoria Therapeutics Inc., filed an amended Form 4/A with the SEC.
- The amendment corrects a clerical error in the original Form 4 filed on April 17, 2025.
- The error involved misreporting the number of derivative securities acquired and the amount of securities underlying those derivatives.
- The original form incorrectly stated 270,000, while the corrected number is 27,000.
- With the correction, the number of derivative securities beneficially owned following the reported transaction is 39,529 shares.
- The options vest monthly over a three-year period, starting September 1, 2024, at a rate of 2.78% per month, subject to continued service with the company.
- The options are exercisable at a price of $5.16.
Sentiment
Score: 7
Explanation: The document is a routine correction of a clerical error in a regulatory filing. It doesn't indicate any fundamental issues with the company, but it does highlight a need for improved accuracy in reporting. The sentiment is neutral to slightly positive as it shows the company is taking steps to rectify errors.
Future Outlook
The options vest over a three-year period, contingent on the CEO's continued service with the company.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the equity-based compensation of key executives.
Stakeholder Impact
- Shareholders benefit from accurate and transparent reporting of executive compensation.
- Employees may be indirectly affected by the perception of management's attention to detail in regulatory filings.
Key Dates
| Date | Description |
|---|---|
| 09/01/2024 | Options vest on a monthly basis over a three-year period at the rate of 2.78% of the shares of Common Stock on the last day of each month following this date until the options are vested. |
| 04/16/2025 | Date of the original transaction involving the stock options. |
| 04/17/2025 | Date of the original Form 4 filing that contained the clerical error. |
| 05/19/2025 | Date of the amended Form 4/A filing to correct the error. |
| 04/16/2035 | Expiration date of the employee stock options. |
Keywords
Form 4, SEC, Neuphoria Therapeutics, Stock Options, Beneficial Ownership, Amendment, Reporting Error, Papapetropoulos, NEUP
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.